The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol

References

• Mackay J Mensah GA The atlas of heart disease and stroke Geneva World Health Organization 2004
   Google Scholar
• Heidenreich PA Trogdon JG Khavjou OA Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association Circulation 2011 123 8 933 944 21262990
   PubMed Web of Science ®Google Scholar
• Kannel WB Dawber TR Kagan A Revotskie N Stokes J3rd Factors of risk in the development of coronary heart disease – six year follow-up experience. The Framingham Study Ann Intern Med 1961 55 33 50 13751193
   PubMed Web of Science ®Google Scholar
• Müller C Xanthoma, hypercholesterolemia, angina pectoris Acta Med Scand Suppl 1938 89 75 84
   Google Scholar
• Yusuf S Hawken S Ounpuu S Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 2004 364 9438 937 952 15364185
   PubMed Web of Science ®Google Scholar
• Lusis AJ Atherosclerosis Nature 2000 407 6801 233 241 11001066
   PubMed Web of Science ®Google Scholar
• Brown MS Goldstein JL A receptor-mediated pathway for cholesterol homeostasis Science 1986 232 4746 34 47 3513311
   PubMed Web of Science ®Google Scholar
• Marduel M Ouguerram K Serre V Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation Hum Mutat 2013 34 1 83 87 22949395
   PubMed Web of Science ®Google Scholar
• Rader DJ Cohen J Hobbs HH Monogenic hypercholesterolemia: new insights in pathogenesis and treatment J Clin Invest 2003 111 12 1795 1803 12813012
   PubMed Web of Science ®Google Scholar
• Seidah NG Benjannet S Wickham L The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation Proc Natl Acad Sci U S A 2003 100 3 928 933 12552133
   PubMed Web of Science ®Google Scholar
• Abifadel M Varret M Rabès JP Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 2003 34 2 154 156 12730697
   PubMed Web of Science ®Google Scholar
• Abifadel M Guerin M Benjannet S Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia Atherosclerosis 2012 223 2 394 400 22683120
   PubMed Web of Science ®Google Scholar
• Maxwell KN Breslow JL Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype Proc Natl Acad Sci U S A 2004 101 18 7100 7105 15118091
   PubMed Web of Science ®Google Scholar
• Benjannet S Rhainds D Essalmani R NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol J Biol Chem 2004 279 47 48865 48875 15358785
   PubMed Web of Science ®Google Scholar
• Park SW Moon YA Horton JD Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver J Bio Chem 2004 279 48 50630 50638 15385538
   PubMed Web of Science ®Google Scholar
• Cohen J Pertsemlidis A Kotowski IK Graham R Garcia CK Hobbs HH Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 Nat Genet 2005 37 2 161 165 15654334
   PubMed Web of Science ®Google Scholar
• Berge KE Ose L Leren TP Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy Arterioscler Thromb Vasc Biol 2006 26 5 1094 1100 16424354
   PubMed Web of Science ®Google Scholar
• Hooper AJ Marais AD Tanyanyiwa DM Burnett JR The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population Atherosclerosis 2007 193 2 445 448 16989838
   PubMed Web of Science ®Google Scholar
• Rashid S Curtis DE Garuti R Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 Proc Natl Acad Sci U S A 2005 102 15 5374 5379 15805190
   PubMed Web of Science ®Google Scholar
• Cohen JC Boerwinkle E Mosley THJr Hobbs HH Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 2006 354 12 1264 1272 16554528
   PubMed Web of Science ®Google Scholar
• Leigh SE Foster AH Whittall RA Hubbart CS Humphries SE Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database Ann Hum Genet 2008 72 Pt 4 485 498 18325082
   PubMed Web of Science ®Google Scholar
• Leigh SE Leren TP Humphries SE Commentary PCSK9 variants: a new database Atherosclerosis 2009 203 1 32 33 19249440
   PubMed Web of Science ®Google Scholar
• Abifadel M Rabès JP Devillers M Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease Hum Mutat 2009 30 4 520 529 19191301
   PubMed Web of Science ®Google Scholar
• Horton JD Shah NA Warrington JA Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes Proc Natl Acad Sci U S A 2003 100 21 12027 12032 14512514
   PubMed Web of Science ®Google Scholar
• Maxwell KN Soccio RE Duncan EM Sehayek E Breslow JL Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice J Lipid Res 2003 44 11 2109 2119 12897189
   PubMed Web of Science ®Google Scholar
• Wenner Moyer M The search beyond statins Nat Med 2010 16 2 150 153 20134459
   PubMed Web of Science ®Google Scholar
• Dubuc G Chamberland A Wassef H Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia Arterioscler Thromb Vasc Biol 2004 24 8 1454 1459 15178557
   PubMed Web of Science ®Google Scholar
• Jung D Kullak-Ublick GA Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression Hepatology 2003 37 3 622 631 12601360
   PubMed Web of Science ®Google Scholar
• Li H Dong B Park SW Lee HS Chen W Liu J Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine J Biol Chem 2009 284 42 28885 28895 19687008
   PubMed Web of Science ®Google Scholar
• Kong W Wei J Abidi P Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins Nat Med 2004 10 12 1344 1351 15531889
   PubMed Web of Science ®Google Scholar
• Cameron J Ranheim T Kulseth MA Leren TP Berge KE Berberine decreases PCSK9 expression in HepG2 cells Atherosclerosis 2008 201 2 266 273 18355829
   PubMed Web of Science ®Google Scholar
• Abidi P Zhou Y Jiang JD Liu J Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine Arterioscler Thromb Vasc Biol 2005 25 10 2170 2176 16100034
   PubMed Web of Science ®Google Scholar
• Cunningham D Danley DE Geoghegan KF Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia Nat Struct Mol Biol 2007 14 5 413 419 17435765
   PubMed Web of Science ®Google Scholar
• Naureckiene S Ma L Sreekumar K Functional characterization of Narc 1, a novel proteinase related to proteinase K Arch Biochem Biophys 2003 420 1 55 67 14622975
   PubMed Web of Science ®Google Scholar
• Seidah NG Mayer G Zaid A The activation and physiological functions of the proprotein convertases Int J Biochem Cell Biol 2008 40 6–7 1111 1125 18343183
   PubMed Web of Science ®Google Scholar
• Seidah NG Prat A The biology and therapeutic targeting of the proprotein convertases Nat Rev Drug Discov 2012 11 5 367 383 22679642
   PubMed Web of Science ®Google Scholar
• Zhao Z Tuakli-Wosornu Y Lagace TA Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 2006 79 3 514 523 16909389
   PubMed Web of Science ®Google Scholar
• Mayne J Dewpura T Raymond A Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture Clin Chem 2011 57 10 1415 1423 21813713
   PubMed Web of Science ®Google Scholar
• Cariou B Ouguerram K Zaïr Y PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia Arterioscler Thromb Vasc Biol 2009 29 12 2191 2197 19762784
   PubMed Web of Science ®Google Scholar
• Mancias JD Goldberg J Structural basis of cargo membrane protein discrimination by the human COPII coat machinery EMBO J 2008 27 21 2918 2928 18843296
   PubMed Web of Science ®Google Scholar
• Chen XW Wang H Bajaj K SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion eLife 2013 2 e00444 23580231
   PubMed Web of Science ®Google Scholar
• McNutt MC Lagace TA Horton JD Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells J Biol Chem 2007 282 29 20799 20803 17537735
   PubMed Web of Science ®Google Scholar
• Thomas G Furin at the cutting edge: from protein traffic to embryogenesis and disease Nat Rev Mol Cell Biol 2002 3 10 753 766 12360192
   PubMed Web of Science ®Google Scholar
• Mayer G Boileau G Bendayan M The proprotein convertase furin colocalizes with caveolin-1 in the Golgi apparatus and endosomes of hepatocytes Cell Tissue Res 2004 316 1 55 63 14986103
   PubMed Web of Science ®Google Scholar
• Mayer G Boileau G Bendayan M Sorting of furin in polarized epithelial and endothelial cells: expression beyond the Golgi apparatus J Histochem Cytochem 2004 52 5 567 579 15100235
   PubMed Web of Science ®Google Scholar
• Boucher E Mayer G Londono I Bendayan M Expression and localization of MT1-MMP and furin in the glomerular wall of short- and long-term diabetic rats Kidney Int 2006 69 9 1570 1577 16541018
   PubMed Web of Science ®Google Scholar
• Benjannet S Rhainds D Hamelin J Nassoury N Seidah NG The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications J Biol Chem 2006 281 41 30561 30572 16912035
   PubMed Web of Science ®Google Scholar
• Essalmani R Susan-Resiga D Chamberland A In vivo evidence that furin from hepatocytes inactivates PCSK9 J Biol Chem 2011 286 6 4257 4263 21147780
   PubMed Web of Science ®Google Scholar
• Mayer G Hamelin J Asselin MC The regulated cell surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates J Biol Chem 2008 283 4 2373 2384 18039650
   PubMed Web of Science ®Google Scholar
• Lipari MT Li W Moran P Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels J Biol Chem 2012 287 52 43482 43491 23135270
   PubMed Web of Science ®Google Scholar
• Allard D Amsellem S Abifadel M Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia Hum Mutat 2005 26 5 497 16211558
   PubMedGoogle Scholar
• Abdiche Y Riggers J Gomes Binventors Pfizer, Rinat Neuroscience Corp, assignee PCSK9 antagonists United States patent US 20100068199A1 3 18 2010
   Google Scholar
• Maxwell KN Fisher EA Breslow JL Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment Proc Natl Acad Sci U S A 2005 102 6 2069 2074 15677715
   PubMed Web of Science ®Google Scholar
• Zhang DW Lagace TA Garuti R Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation J Biol Chem 2007 282 25 18602 18612 17452316
   PubMed Web of Science ®Google Scholar
• Kwon HJ Lagace TA McNutt MC Horton JD Deisenhofer J Molecular basis for LDL receptor recognition by PCSK9 Proc Natl Acad Sci U S A 2008 105 6 1820 1825 18250299
   PubMed Web of Science ®Google Scholar
• Nassoury N Blasiole DA Tebon Oler A The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR Traffic 2007 8 6 718 732 17461796
   PubMed Web of Science ®Google Scholar
• Wang Y Huang Y Hobbs HH Cohen JC Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR J Lipid Res 2012 53 9 1932 1943 22764087
   PubMed Web of Science ®Google Scholar
• Lagace TA Curtis DE Garuti R Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice J Clin Invest 2006 116 11 2995 3005 17080197
   PubMed Web of Science ®Google Scholar
• Malby S Pickering R Saha S Smallridge R Linse S Downing AK The first epidermal growth factor-like domain of the low-density lipoprotein receptor contains a noncanonical calcium binding site Biochemistry (Mosc) 2001 40 8 2555 2563
   Web of Science ®Google Scholar
• Yamamoto T Lu C Ryan RO A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor J Biol Chem 2011 286 7 5464 5470 21149300
   PubMed Web of Science ®Google Scholar
• Zhang DW Garuti R Tang WJ Cohen JC Hobbs HH Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor Proc Natl Acad Sci U S A 2008 105 35 13045 13050 18753623
   PubMed Web of Science ®Google Scholar
• Poirier S Mayer G Poupon V Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route J Biol Chem 2009 284 42 28856 28864 19635789
   PubMed Web of Science ®Google Scholar
• Benjannet S Saavedra YG Hamelin J Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events J Biol Chem 2010 285 52 40965 40978 20937814
   PubMed Web of Science ®Google Scholar
• Holla ØL Laerdahl JK Strøm TB Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor Biochem Biophys Res Commun 2011 406 2 234 238 21324305
   PubMed Web of Science ®Google Scholar
• Sun H Samarghandi A Zhang N Yao Z Xiong M Teng BB Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor Arterioscler Thromb Vasc Biol 2012 32 7 1585 1595 22580899
   PubMed Web of Science ®Google Scholar
• Fisher TS Lo Surdo P Pandit S Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation J Biol Chem 2007 282 28 20502 20512 17493938
   PubMed Web of Science ®Google Scholar
• Kosenko T Golder M Leblond G Weng W Lagace TA Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation J Biol Chem 2013 288 12 8279 8288 23400816
   PubMed Web of Science ®Google Scholar
• Lo Surdo P Bottomley MJ Calzetta A Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH EMBO Reports 2011 12 12 1300 1305 22081141
   PubMed Web of Science ®Google Scholar
• Bottomley MJ Cirillo A Orsatti L Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants J Biol Chem 2009 284 2 1313 1323 19001363
   PubMed Web of Science ®Google Scholar
• Tveten K Holla ØL Cameron J Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification Hum Mol Genet 2012 21 6 1402 1409 22156580
   PubMed Web of Science ®Google Scholar
• Du F Hui Y Zhang M Linton MF Fazio S Fan D Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein J Biol Chem 2011 286 50 43054 43061 22027821
   PubMed Web of Science ®Google Scholar
• Ni YG Condra JH Orsatti L A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake J Biol Chem 2010 285 17 12882 12891 20172854
   PubMed Web of Science ®Google Scholar
• Strøm TB Holla ØL Tveten K Cameron J Berge KE Leren TP Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain Mol Genet Metab 2010 101 1 76 80 20659812
   PubMed Web of Science ®Google Scholar
• Mayer G Poirier S Seidah NG Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels J Biol Chem 2008 283 46 31791 31801 18799458
   PubMed Web of Science ®Google Scholar
• Seidah NG Poirier S Denis M Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation PLoS One 2012 7 7 e41865 22848640
   PubMed Web of Science ®Google Scholar
• Timms KM Wagner S Samuels ME A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree Hum Genet 2004 114 4 349 353 14727179
   PubMed Web of Science ®Google Scholar
• Leren TP Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia Clin Genet 2004 65 5 419 422 15099351
   PubMed Web of Science ®Google Scholar
• Naoumova RP Tosi I Patel D Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response Arterioscler Thromb Vasc Biol 2005 25 12 2654 2660 16224054
   PubMed Web of Science ®Google Scholar
• McNutt MC Kwon HJ Chen C Chen JR Horton JD Lagace TA Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells J Biol Chem 2009 284 16 10561 10570 19224862
   PubMed Web of Science ®Google Scholar
• Shan L Pang L Zhang R Murgolo NJ Lan H Hedrick JA PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide Biochem Biophys Res Commun 2008 375 1 69 73 18675252
   PubMed Web of Science ®Google Scholar
• Liu M Wu G Baysarowich J PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain J Lipid Res 2010 51 9 2611 2618 20453200
   PubMed Web of Science ®Google Scholar
• Zhang Y Zhou L Kong-Beltran M Calcium-independent inhibition of PCSK9 by affinity-improved variants of the LDL receptor EGF(A) domain J Mol Biol 2012 422 5 685 696 22728257
   PubMed Web of Science ®Google Scholar
• O’Keefe JHJr Cordain L Harris WH Moe RM Vogel R Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal J Am Coll Cardiol 2004 43 11 2142 2146 15172426
   PubMed Web of Science ®Google Scholar
• Baigent C Blackwell L Emberson J Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 2010 376 9753 1670 1681 21067804
   PubMed Web of Science ®Google Scholar
• Kapur NK Musunuru K Clinical efficacy and safety of statins in managing cardiovascular risk Vasc Health Risk Manag 2008 4 2 341 353 18561510
   PubMedGoogle Scholar
• Hou R Goldberg AC Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety Endocrinol Metab Clin North Am 2009 38 1 79 97 19217513
   PubMed Web of Science ®Google Scholar
• Bruckert E Hayem G Dejager S Yau C Begaud B Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study Cardiovasc Drugs Ther 2005 19 6 403 414 16453090
   PubMed Web of Science ®Google Scholar
• Duff CJ Scott MJ Kirby IT Hutchinson SE Martin SL Hooper NM Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor Biochem J 2009 419 3 577 584 19196236
   PubMed Web of Science ®Google Scholar
• Chan JC Piper DE Cao Q A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates Proc Natl Acad Sci U S A 2009 106 24 9820 9825 19443683
   PubMed Web of Science ®Google Scholar
• Ni YG Di Marco S Condra JH A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo J Lipid Res 2011 52 1 78 86 20959675
   PubMed Web of Science ®Google Scholar
• Condra J Cubbon R Hammond Hinventors Merck assignee 1D05 PCSK9 antagonists United States patent US 20120301461A1 11 12 2012
   Google Scholar
• Zhang L McCabe T Condra JH An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes Int J Biol Sci 2012 8 3 310 327 22355267
   PubMed Web of Science ®Google Scholar
• Liang H Chaparro-Riggers J Strop P Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates J Pharmacol Exp Ther 2012 340 2 228 236 22019884
   PubMed Web of Science ®Google Scholar
• Chaparro-Riggers J Liang H DeVay RM Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 J Biol Chem 2012 287 14 11090 11097 22294692
   PubMed Web of Science ®Google Scholar
• Davies J Darling R Allan BInventors Eli Lilly and Company, assignee Antibodies to PCSK9 and uses thereof US patent US 20130071405A1 3 21 2013
   Google Scholar
• Stein EA Mellis S Yancopoulos GD Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 2012 366 12 1108 1118 22435370
   PubMed Web of Science ®Google Scholar
• McKenney JM Koren MJ Kereiakes DJ Hanotin C Ferrand AC Stein EA Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 2012 59 25 2344 2353 22463922
   PubMed Web of Science ®Google Scholar
• Roth EM McKenney JM Hanotin C Asset G Stein EA Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 2012 367 20 1891 1900 23113833
   PubMed Web of Science ®Google Scholar
• Dias CS Shaywitz AJ Wasserman SM Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins J Am Coll Cardiol 2012 60 19 1888 1898 23083772
   PubMed Web of Science ®Google Scholar
• Sullivan D Olsson AG Scott R Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial JAMA 2012 308 23 2497 2506 23128163
   PubMed Web of Science ®Google Scholar
• Raal F Scott R Somaratne R Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 2012 126 20 2408 2417 23129602
   PubMed Web of Science ®Google Scholar
• Koren MJ Scott R Kim JB Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 2012 380 9858 1995 2006 23141812
   PubMed Web of Science ®Google Scholar
• Giugliano RP Desai NR Kohli P Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 2012 380 9858 2007 2017 23141813
   PubMed Web of Science ®Google Scholar
• Pfizer Monthly and twice monthly subcutaneous dosing of PF-04950615 (RN316) in hypercholesterolemic subjects on a statin Available from: http://clinicaltrials.gov/ct2/show/NCT01592240. http://clinicaltrials.gov/ct2/show/NCT01592240. NLM identifier: NCT01592240Accessed September 12, 2013
   Google Scholar
• Rue S Cohen S Li J Yowe Dinventors IRM LLC, Novartis AG, assignee PCSK9 antagonists United States patent US 20110142849A1 6 16 2011
   Google Scholar
• Novartis Pharmaceuticals Safety, pharmacokinetics and pharmacodynamics of LGT209 in healthy volunteers with elevated cholesterol and in hypercholesterolemic patients treated with statins Available from: http://www.clinicaltrials.gov/ct2/show/NCT00265317. http://clinicaltrials.gov/ct2/show/NCT01859455. NLM identifier: NCT01859455Accessed September 12, 2013
   Google Scholar
• Genentech A phase II study of the safety and efficacy of MPSK3169A in patients with coronary heart disease or high risk of coronary heart disease Available from: http://clinicaltrials.gov/ct2/show/NCT01609140. http://clinicaltrials.gov/ct2/show/NCT01609140. NLM identifier: NCT01609140Accessed September 12, 2013
   Google Scholar
• Poirier S Mayer G Benjannet S The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 J Biol Chem 2008 283 4 2363 2372 18039658
   PubMed Web of Science ®Google Scholar
• Canuel M Sun X Asselin MC Paramithiotis E Prat A Seidah NG Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1) PLoS One 2013 8 5 e64145 23675525
   PubMed Web of Science ®Google Scholar
• Jonas MC Costantini C Puglielli L PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1 EMBO Reports 2008 9 9 916 922 18660751
   PubMed Web of Science ®Google Scholar
• Sharotri V Collier DM Olson DR Zhou R Snyder PM Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9) J Biol Chem 2012 287 23 19266 19274 22493497
   PubMed Web of Science ®Google Scholar
• Labonté P Begley S Guévin C PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression Hepatology 2009 50 1 17 24 19489072
   PubMed Web of Science ®Google Scholar
• Hofer F Gruenberger M Kowalski H Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus Proc Natl Acad Sci U S A 1994 91 5 1839 1842 8127891
   PubMed Web of Science ®Google Scholar
• Finkelshtein D Werman A Novick D Barak S Rubinstein M LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus Proc Natl Acad Sci U S A 2013 110 18 7306 7311 23589850
   PubMed Web of Science ®Google Scholar
• Agnello V Abel G Elfahal M Knight GB Zhang QX Hepatitis C virus and other faviviridae viruses enter cells via low density lipoprotein receptor Proc Natl Acad Sci U S A 1999 96 22 12766 12771 10535997
   PubMed Web of Science ®Google Scholar
• Pileri P Uematsu Y Campagnoli S Binding of hepatitis C virus to CD81 Science 1998 282 5390 938 941 9794763
   PubMed Web of Science ®Google Scholar
• Marlovits TC Abrahamsberg C Blaas D Very-low-density lipoprotein receptor fragment shed from HeLa cells inhibits human rhinovirus infection J Virol 1998 72 12 10246 10250 9811769
   PubMed Web of Science ®Google Scholar
• Sanofi Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727) (ODYSSEY outcomes) Available from: http://clinicaltrials.gov/ct2/show/NCT01663402. http://clinicaltrials.gov/ct2/show/NCT01663402. NLM identifier: NCT01663402Accessed September 12, 2013
   Google Scholar
• Amgen Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) Available from: http://clinicaltrials.gov/ct2/show/NCT01764633. http://clinicaltrials.gov/ct2/show/NCT01764633. NLM identifier: NCT01764633Accessed September 12, 2013
   Google Scholar
• Amgen GLobal Assessment of plaque reGression with a PCSK9 antibOdy as measured by intraVascular ultrasound (GLAGOV) Available from: http://clinicaltrials.gov/ct2/show/NCT01813422. http://clinicaltrials.gov/ct2/show/NCT01813422. NLM identifier: NCT01813422Accessed September 12, 2013
   Google Scholar
• Amgen Trial evaluating PCSK9 antibody in subjects with LDL receptor abnormalities (TESLA) Available from: http://clinicaltrials.gov/ct2/show/NCT01588496. http://clinicaltrials.gov/ct2/show/NCT01588496. NLM identifier: NCT01588496Accessed September 12, 2013
   Google Scholar
• Cannon CP Braunwald E McCabe CH Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 2004 350 15 1495 1504 15007110
   PubMed Web of Science ®Google Scholar
• Law MR Wald NJ Rudnicka AR Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 2003 326 7404 1423 12829554
   PubMed Web of Science ®Google Scholar
• Mihaylova B Emberson J Blackwell L The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 2012 380 9841 581 590 22607822
   PubMed Web of Science ®Google Scholar
• Ridker PM Danielson E Fonseca FA Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 2009 373 9670 1175 1182 19329177
   PubMed Web of Science ®Google Scholar
• Ridker PM Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep 2013 15 1 295 23225175
   PubMed Web of Science ®Google Scholar
• Sun XM Eden ER Tosi I Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia Hum Mol Genet 2005 14 9 1161 1169 15772090
   PubMed Web of Science ®Google Scholar
• Herbert B Patel D Waddington SN Increased secretion of lipoproteins in transgenic mice expressing human D374YPCSK9 under physiological genetic control Arterioscler Thromb Vasc Biol 2010 30 7 1333 1339 20448210
   PubMed Web of Science ®Google Scholar
• Denis M Marcinkiewicz J Zaid A Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice Circulation 2012 125 7 894 901 22261195
   PubMed Web of Science ®Google Scholar
• Al-Mashhadi RH Sørensen CB Kragh PM Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant Sci Transl Med 2013 5 166 166ra161
   Web of Science ®Google Scholar
• Rudenko G Henry L Henderson K Structure of the LDL receptor extracellular domain at endosomal pH Science 12 20 2002 298 5602 2353 2358 12459547
   PubMed Web of Science ®Google Scholar